Indications and limitations of vismodegib for basal cell carcinoma

JAMA Ophthalmology

Volumn 132, Issue 7, 2014, Pages 905-906

  Yin, Vivian T ^a   Sniegowski, Matthew ^a   Esmaeli, Bita ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VISMODEGIB;

ADVANCED CANCER; BASAL CELL CARCINOMA; BASAL CELL NEVUS SYNDROME; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; HUMAN; LETTER; OFF LABEL DRUG USE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; TUMOR REGRESSION; TUMOR VOLUME;

ANILIDES; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; EYELID NEOPLASMS; FEMALE; HUMANS; MALE; ORBITAL NEOPLASMS; PYRIDINES; SKIN NEOPLASMS;

EID: 84904204250     PISSN: 21686165     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaophthalmol.2014.1787     Document Type: Letter

References (4)

1. Gill HS, Moscato EE, Chang ALS, Soon S, Silkiss RZ. Vismodegib for periocular and orbital basal cell carcinoma. JAMA Ophthalmol. 2013;131(12):1591-1594.
2. Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171-2179.
3. Yin VT, Pfeiffer ML, Esmaeli B. Targeted therapy for orbital and periocular basal cell carcinoma and squamous cell carcinoma. Ophthal Plast Reconstr Surg. 2013;29(2):87-92.
4. Tang JY, Mackay-Wiggan JM, Aszterbaum M, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med. 2012;366 (23):2180-2188.